Patent Application
20230320660
The present invention relates to the field of monitoring cardiac function.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each such individual publication or patent application were specifically and individually indicated to be so incorporated by reference.
Heart failure (HF) is the leading cause of hospitalization among adults over 65 years of age in the United States. In 2014, more than 5.1 million people in the United States were living with a diagnosis of HF, and as many as one in nine deaths each year can be attributed to complications stemming from this disease. Acute decompensation is a life-threatening consequence of HF that occurs when uncontrolled fluid retention in the thoracic cavity prevents the heart from maintaining adequate circulation. An important component of managing HF patients is maintaining an appropriate fluid volume by adjusting the patient's medications in response to his/her cardiac function. Fluid volume metrics, such as dyspnea, edema, and weight gain, can be monitored by patients at home as an indirect indicator of worsening cardiac function, but are highly non-specific and cannot predict decompensation risk with sufficient resolution to affect the hospitalization rate. Recent evidence has shown that directly monitoring cardiac function via an implantable sensor can provide clinicians with a remote monitoring tool to determine when medication adjustments can prevent decompensation and the need for hospitalization. However, the cost and invasive nature of these sensors severely restrict their potential for clinical adoption.
Various mechanisms have been employed to determine cardiac function and health. These include invasive technologies such as the Swan Ganz catheter and a pulmonary artery implant to less invasive technologies such as arterial waveform monitoring devices, and surface worn technologies such as bioimpedance monitors and noncontact technologies such as scales to monitor weight. The invasive technologies are more accurate but also more risky while the noninvasive technologies have less risk but are more cumbersome and typically less accurate. The presence of collected fluid, peripheral edema, ascites, pleural effusions and weight can also be used to monitor cardiac function in CHF patients, but these parameters are merely symptomatic surrogates with poor correlation to actual cardiac output.
What is needed is a simple, repeatable, accurate monitor of cardiac function and other physiologic parameters that allows consistent measurement of cardiac output in the clinic, hospital and/or home environment. The present invention provides an easy to use, home-based device and method for the tracking of cardiac output, stroke volume and cardiac function. The invention can also be used for monitoring mechanical phases of the cardiac cycle, which are useful for diagnosing structural issues such as heart valve pathologies.
The present invention is a non-invasive respiratory monitor that is capable of directly monitoring cardiac function in a remote setting. The respiratory monitor, or airway device/controller, detects minor variations in expiratory airflow pressure known as cardiogenic oscillations (COS), which are generated by changes in the pulmonary blood volume that correspond with the cardiac cycle. The strength, or magnitude, or variations in magnitude, of cardiac oscillations is a direct indicator of cardiac function and is directly correlated with stroke volume and inversely proportional to pulmonary artery pressure.
Minor, cyclic waveforms caused by cardiogenic oscillations, or cardiac pulses, can be detected in the bulk pressure and flow measurements of expiration and inspiration. The method and device of the present invention utilizes this ability to detect and isolate cardiac oscillations, or pulsations, within the sensed pressure profile in the airway of an animal or human. Pressure measured at around 100 Hz, or around 80 Hz to around 120 Hz, within the airway of a subject allows for excellent resolution of the pressure signal. When pressure in the airway is measured at this frequency, cardiogenic oscillations may be visible in the resulting pressure curve. These pulsations are best seen at end expiration, or during a breath hold, but can be seen throughout the breathing cycle. This result may be the result of the heart beating in close proximity to the lungs, which subsequently transmits the pressure fluctuations through the trachea to the mouth and nose. It may also be the result of pulmonary blood flow, which may slightly compress the lungs as the heart beats.
The magnitude of cardiac oscillations is indicated by the standard deviation, or variations, of the cardiac oscillation pressure waveform and is a direct indicator of cardiac function and is directly correlated with stroke volume and inversely proportional to pulmonary artery pressure. The cardiac performance of patients with heart failure is reduced when compared to that of healthy individuals, which will dampen the cardiac oscillation curve relative to healthy subjects.
In one embodiment of an airway device as described herein, the device may generally comprise a mouthpiece section and an opening section defining one or more airway lumens therethrough. The airway device may further comprise a first sensor in fluid communication with the one or more airway lumens and configured to detect an airway pressure when a user inhales or exhales through the one or more airway lumens, a second sensor positioned upon a hand-piece for contact against a portion of the user and configured to detect a physiological signal from the user, and a controller in communication with the first and second sensors, wherein the controller is programmed to correlate pressure oscillations in the airway pressure received from the first sensor with heartbeats received from the first sensor, the second sensor, or pressure data corresponding to a rough airway pressure
In one embodiment of a method of correlating physiologic parameters, the method may generally comprise detecting via a first sensor an airway pressure of a user while inhaling or exhaling through one or more airway lumens of a respiration device having a mouthpiece section and an opening section, detecting via a second sensor positioned upon a hand-piece of the respiration device a physiological signal sensed from the user in contact with the second sensor, and correlating via a controller pressure oscillations in the airway pressure received from the first sensor with a timing of heartbeats received from the first sensor, the second sensor, or pressure data corresponding to a rough airway pressure.
The present invention senses pressure and/or flow within the airway by exposing the airway (via the patient's nose or mouth) to one or more pressure, flow, and/or other sensor(s). When the epiglottis is opened, this exposure to the airway allows pressure and/or flow sensors to detect small pulsations that occur during heart function. These fluctuations may also be detected with a sensitive enough sensor, when the epiglottis is closed. With an appropriately sensitive sensor sampling at a rapid frequency, waveforms can be seen in the airway corresponding to contractions, relaxation and valve openings in the heart. This phenomenon has been found to be repeatable and allows not only for tracking of heart and lung function and/or conditions (i.e. pulmonary edema, pleural effusions, congestive heart failure, aortic insufficiency, mitral, pulmonic, tricuspid insufficiency, etc.) but can be used to diagnose disease in patients using the airway device. Whereas ECG is used to monitor and diagnosis heart conditions based on the electrical signal being sent to the heart, the present invention provides additional information based on the actual mechanical function of the heart.
Preferably, the amplitude and/or area under the curves for pressure and/or flow data can be used to determine relative pulmonary blood flow, relative stroke volume, and/or relative pulmonary artery pressure. For example, as pulmonary blood flow increases, the amplitudes of the flow pulsations in the breath increase. Additional parameters, such as the slope of the pressure curve, changes in the curve or standard deviation of the curve can also be used to determine relative cardiac function. When tracked over time, these parameters provide noninvasive insights into the patient's changing cardiac health and can be used to adjust his/her care accordingly. This is particularly useful for people who are being monitored regularly for changes in their conditions, such as patients with heart failure. Patient pressure/flow curve data can also be compared to those of healthy or unhealthy patient populations to asses a particular patient's, or a group of patients', health
In some embodiments, the patient is prompted by a controller to breathe into the device naturally for several cycles. This may be done automatically by a controller. Further, the airway device may be simply placed in the mouth and worn while going about activities of daily living to allow for natural sensing of respiratory rate, another powerful predictor and indicator of progressing illness. In some embodiments, the airway device/controller can calculate the rate of exhalation and capture cardiogenic oscillations at the same phase of breathing for each patient to allow for consistent measures of cardiac output and lung function. In other embodiments, the mean or median of the samples may be used as the representative value for that particular measurement. For example, the patient may breath regularly for 2, 5, or 10 minutes, during which the pressure, flow, and other signals are captured, and at the end the of the session values such as the average amplitude of the signal caused by cardiogenic oscillations may be reported. In this way intra-measurement variability is reduced and the signal-to-noise ratio is improved.
Further, in some embodiments, the patient may be prompted by a controller to inhale deeply and hold his/her breath (or, if used in conjunction with a ventilator, the ventilator can be paused at end inhalation, end exhalation, or elsewhere, either manually or, preferably, automatically with communication between airway device/controller and the ventilator or incorporation of airway device/controller into the ventilator) to see the impact of breathing on the pressure waveform. Variability in the respiratory pulse pressure waveform can be used to determine hydration status, as well as volume status. Dehydrated or hypovolemic patients will see a pulse pressure waveform that varies throughout the respiratory cycle due to the change in cardiac function with the changing thoracic pressures found with respiration. As fluid status is restored, this variability is reduced and lack of variability can provide a powerful indicator that fluid status has been restored. In addition to pulse pressure variability, heart rate variability may also be used to assess fluid status. Variability may be assessed on a continuous basis during natural or mechanical ventilation or may be assessed during a respirator pause to look for changes at end-inspiration and/or end-expiration over time to track variability. The ratio of end-inspiratory to end-expiratory pulse amplitude during respiration or with a breath hold may be determined. Variations in waveform peak-to-peak period and magnitude, in addition to other parameters, may be determined.
In some embodiments, the patient may be prompted by a controller to exhale against resistance, while leaving his/her throat open (i.e., leaving the glottis and/or epiglottis open). This is referred to as a “modified Valsalva maneuver” or MVM. The patient/user may be prompted to exhale within a specific pressure range and for a specific time period. For example, the user may be prompted to exhale at a pressure of 10 mm Hg (±0.5 mm Hg) for at least 5 seconds. “Exhaling” may include exhaling into a closed or open system. If the system is open, for example, with a resistance control orifice, the resistance control orifice must be small enough to allow the user to exhale at the given pressure for the given time frame. In other words, the vent can't allow more than a breath's air capacity to escape at the required MVM pressure. The user may be prompted by the controller, or instructed, to perform the MVM within the proper parameters (open throat, pressure, and time).
A respiratory pause may also be used to provide another determinant of cardiac output-change in end-tidal CO2 after a respirator pause. The use of respiratory pulse pressure waveform analysis in conjunction with the end tidal CO2 method may improve the accuracy of the results and make this method less susceptible to pulse pressure variability.
In addition, actual, or absolute, cardiac output can be determined without calibration using the airway device/controller. By combining the airway device/controller with spirometry or a ventilator, the volume of air in the lung can be accurately estimated. In addition, actual, or absolute, cardiac output can be determined using a CO2 sensor to determine end tidal CO2, as well as an air flow sensor and oxygen sensor. The calculations to determine cardiac output can be performed as described in “Noninvasive Monitoring Cardiac Output Using Partial CO2 Rebreathing” by Brian P. Young, MD, and Lewis L. Low, MD. A spirometer and/or ventilator may be stationary or ambulatory, or may be miniature and built into the mouthpiece itself.
In another embodiment, absolute stroke volume, cardiac output, and/or pulmonary artery pressure can be estimated by comparing the amplitude of the pressure or flow curves in the airway to the volume of air in the lungs and using correlation coefficients based on patient based variables such as their gender and height, in a similar manner to the way correlation coefficients can be use with pulse-transit-time to estimate blood pressure (see Gesche, Heiko, et al. “Continuous blood pressure measurement by using the pulse transit time: comparison to a cuff-based method.” (2011)). In this manner, the present invention may be used to estimate the actual volume displaced in the lung by the cardiac pulse, which represents the true stroke volume. An ECG or pulse oximetry signal may be used to help determine the pulse transit time.
Furthermore, in the setting of low pulse pressure variability this technique can also be used to calculate the dead space in the lung. This can be done by comparing the cardiac pulse pressure waveform at end-inhalation and end-exhalation. If tidal volume is known (i.e. with spirometry or mechanical ventilation), then, assuming the cardiac pulse is a constant, one can calculate the dead space in the lung by looking at the magnitude of the cardiac pressure pulse and calculating the predicted amplitude of the cardiac pulse, measuring the actual amplitude of the cardiac pulse, and determining the dead space information from the difference between the two (due to the extra dead space being compressed also). Total lung volume may also be calculated by the application of a fixed amount of analyte or a small bolus of gas/air to the lung then calculating the resulting concentration of the analyte or the final pressure after delivery of the bolus of air (assuming a breath hold at end-inspiration).
Due to its ease of use and non-invasive nature, the present invention lends itself well to home healthcare monitoring. In a preferred embodiment, the airway device will be handheld or body worn (but does not need to be). The airway device may continuously or intermittently measure flow rates/volumes, pressure, temperature, and/or gas concentrations in the airway. Patient manipulations may be requested by the airway device/controller (i.e. “Breathe deep then hold your breath for 5 seconds”) and the airway device/controller may be able to automatically or manually communicate the extracted information to the patient and/or healthcare provider, or with a mobile device, computer, server or other device. Alerts may be programmed into the airway device and/or controller, as well, to warn of impending issues or danger, or to guide the user through its use. By continuously sensing the pressure, the airway device/controller may also provide continuous feedback on the adequacy of the patient manipulations (i.e. “Slow down the speed of your breath”) to optimize the patient manipulations for improved data capture. Alerts may be audible, visual, vibration, etc. Alerts may also be sent to a physician, monitor, hospital, EMR etc. Alerts may be transferred wirelessly to any device including a mobile device, computer, server, etc.
In temperature-sensing embodiments, the airway device/controller may sense inhaled and exhaled temperature and the controller, based on flow/heat exchange algorithms, reports the patient's temperature. Alternatively, the airway device/controller may report trends in temperature based on baseline data acquired when the patient was at a normal temperature. This deviation from baseline data can be utilized with any of the sensed parameters thereby allowing for the determination of a relative change in any of the parameters without knowing the actual value of any of the parameters.
In any of the home health, clinic or hospital embodiment of the airway device/controller of present invention, additional functionality may be incorporated, including temperature sensing, respiratory function monitoring (i.e. spirometry), acoustic monitoring (to track wheezing in asthmatics, etc.), detection of analytes and/or compounds in the breath (i.e. urea, markers of infection, O2, CO2, water vapor, etc.), detection of analytes in the saliva (since the device may be placed inside the mouth in some embodiments). Additional air sensors may include alcohol, and/or other drugs such as narcotics, marijuana, tobacco, etc.
In addition, physical sensors in contact with the body, for example the lips, fingers, hands, may include ECG sensors, pulse sensors, mucosal contact sensors, etc. When ECG sensors are in place, sampling of the pulsatile signals in the breath from the cardiogenic oscillations may be synchronized with the ECG signal in order to identify periodic signals, evaluate only the relevant portions of the signal and to reduce the amount of noise. For example, the magnitude of change in the pressure and/or flow signals during a set amount of time (such as 200 or 500 ms) may be the variable of interest that is tracked over time to monitor the cardiac health of the patient. A 2-lead ECG may also be used. The R wave, of the ECG signal may be used for synchronization. Pulse oximetry may also be used.
The amplitude of cardiac oscillations is directly affected by pulmonary blood flow (PBF) in a linear manner, and the amplitude of this cardiac oscillation peak is likely correlated to the pulmonary blood volume variation (PBVV), which is defined as the change in the pulmonary blood volume from systole to diastole. PBVV has previously been investigated as a metric of cardiac function during heart failure. The PBVV reflects an increase in capillary volume that impinges upon the compliant bronchiole network leading to the alveoli of the lung and generates high frequency peaks in airway pressure during systole phase of the cardiac cycle. These peaks of cardiac oscillations can be detected. PBVV is proportional to the stroke volume and both values decrease as the cardiac output declines during heart failure. PBVV is also inversely proportional to increases in vascular resistance coincident with heart failure, which restrict the ability of the pulmonary capillaries to expand into the pulmonary airways and contribute to pulmonary hypertension. Thus, the standard deviation of cardiac oscillations (SDCOS) is directly proportional to cardiac output and inversely proportional to pulmonary artery pressure (PAP):
SDCOS∝a*(−ΔPAP)+b*ΔPBF
where a and b are constants representing compliance of the pulmonary arteries and bronchioles, respectively.
Pulmonary Arterial Compliance
Pulmonary Arterial Compliance (PAC) is related to Cardiac Heart Failure (CHF) and is a strong indicator of CHF. As the pulmonary artery becomes congested, PAP increases, as PAP increases, the pulmonary artery stretches. But, at higher pressures (above about 25 mmHg), the pulmonary artery becomes less able to stretch further which leads to increased pulse pressure within the pulmonary artery (pulmonary artery pulse pressure, or PAPP). As a result of the higher pressures within the pulmonary artery, more work is required from the right ventricle, and stroke volume (SV) is increased.
PAC can be Calculated as SV/PAPP (mL/mmHg)
Pulmonary arterial compliance has been shown to be a strong indicator of cardiovascular death or complications. As PAC decreases, the chance of cardiovascular complications or death increases. In addition, treatments for heart failure have been shown to increase the PAC. Currently, the only reliable way to measure PAC is with an invasive catheterization procedure.
Cardiogenic oscillations are generated by the cardiac pulsation in the pulmonary vasculature and are directly related to PAC. As heart failure worsens, stroke volume may decrease which leads to a decrease in the PAC amplitude. Also, PAP increases, the pulmonary artery stiffens, and PAPP increases, also leading to a decrease in the PAC amplitude. A decrease in PAC or PAC amplitude, is a strong indicator of worsening heart health. Amplitude in this instance refers to peak-to-peak amplitude of the curve.
In one use case example, the airway device/controller can be used to track a patient with congestive heart failure. If the patient using the airway device/controller is found to have decreased stoke volume or increased pulmonary artery pressure (via the pressure and/or flow sensors), decreased lung volume and/or decreased respiratory compliance due to fluid accumulation in the pleura and/or pulmonary spaces (via spirometer or pressure sensor) and/or enlargement of the heart, increased pathologic lung sounds (via the acoustic sensor/microphone), increased end-tidal CO2 and/or an increased respiratory rate (via the pressure sensor or spirometer) then the healthcare provider or patient may be alerted that their condition is worsening.
In the home healthcare embodiment, the patient may then be sent home with a networked device (or return to the clinic) for repeat measurements. In the instance where this device is used in combination with daily weighings on a networked scale, the airway device/controller may communicate with an existing network provided by the scale or other in-home patient monitoring device, or any network, to alert the user and/or healthcare provider. In this way, the patient's cardiac health can be monitored remotely and noninvasively. This technique may also be used in lieu of radiographic examination to look for pneumo- or hemo-thorax following a procedure. Tension pneumothorax and detection of any other lung pathology may be accomplished with this technology, as well, in the hospital, office, or home setting.
In an alternative embodiment, the airway device/controller may record noises directly within the respiratory tract. In this embodiment, the airway device/controller may incorporate a disposable or reusable microphone attached to the airway device, (or alternatively, to a ventilator, vent tube or endotracheal tube). The microphone can track respiratory sounds and rapidly report the onset of respiratory distress, pneumonia, rales, rhonchi or other changes in lungs sounds. In its preferred embodiment the airway device/controller may incorporate noise cancellation functions. In one such embodiment, two microphones may be used within the airway device with one microphone facing the airway and the other microphone in a similar position within the airway device but sealed off from the airway. The signal from the sealed off microphone may then be subtracted from the microphone open to the airway thereby cancelling out ambient noise and allowing resolution of the physiologic sounds (cardiac, respiratory, gastrointestinal, etc.).
In some embodiments, the airway device/controller could be used in the placement and/or continuous monitoring of an endotracheal tube (ET). ET placement is related to causes of infection in ventilator-acquired pneumonia patients: poor placement can lead to pooling of fluid and, within the fluid, bacterial colonization can occur which then can migrate through the ET or around the cuff of the ET and into the lungs. Pooling of fluid and/or changes in respiratory flow/pressure can be monitored to obtain an early onset indication of infection. Bacteria may also be detected through sensors on the device.
In yet another embodiment, the airway device/controller can detect pathologic behavior of the heart valves. For example, when used in combination with an ECG, the expected mechanical heart behavior and timing of the cardiac cycle is known. By comparing the electrical and mechanical signals, improper mechanical function can be detected, such as the timing of the contraction of the atria or ventricles and opening or closing of the heart valves. Furthermore, the intensity and timing of these signals can also be used to diagnosis pathologies—for example, whether certain phases of the cardiac cycle are prolonged or incomplete, such as with mitral valve regurgitation. This information may be used alone or in combination with the sound information described above or with any other technique for diagnosing heart murmurs in order to better understand the underlying heart function or dysfunction.
This and any of the embodiments described herein may be utilized in a continuous or intermittent manner. The airway device may be designed to be worn by the user or require additional equipment to function and may be applied to the nose and/or mouth or applied directly to an endotracheal tube. The airway device/controller and any or all of its functions may be used in any setting including: the home, office, clinic, hospital ward, ASC or ICU.
The airway device/controller may be used to monitor chronic conditions and/or detect acute conditions including: COPD, asthma, CHF, cancer, stroke, pulmonary embolism, and any other condition that could have an impact on respiratory rate, temperature, stroke volume, heart rate, tidal volume, lung sounds, heart sounds, GI sounds, pO2, pCO2, pH, or any other of the monitored parameters.
The airway device may incorporate a controller to analyze the signals from the various sensors. Alternatively, all, or part, of a controller may exist separately from the airway device and communicate with the airway device either wirelessly (via internet, intranet, WAN, LAN or other network, or it may be local via Bluetooth, Wi-Fi, etc.) or wired. If the connection is wired, it may be continuous or intermittent. For example, the data from the airway device may be periodically transmitted via a USB connection or other type of connection after data has been collected. A wireless connection may also be continuous or intermittent. The controller may be, or communicate with, one or more mobile devices, computers, servers, etc.
The airway device contains one or more sensors which can measure and/or calculate airway pressure, airway flow, temperature, sounds, respiratory rate, stroke volume, heart rate, tidal volume, lung sounds, heart sounds, GI sounds, pO2, pCO2, pH, ECG, pulse rate, pulse pressure, spirometry, analytes and/or compounds in the breath (i.e. urea, markers of infection, O2, CO2, urea, water vapor, alcohol, drugs, etc.) or analytes and/or compounds in the saliva, such as glucose, etc.
A controller is either incorporated into the airway device or a separate device which communicates with the airway device either wirelessly or via a wired connection. The controller may be incorporated into a ventilator, a CPAP, a stand-alone device or incorporated into, or in communication with, a computer and/or smartphone.
In a preferred embodiment, the controller is incorporated into a smartphone which communicates wirelessly with the airway device, either on a continuous or intermittent basis. Data transferred from the controller may also be transmitted to/from a remote server, for example, via the internet or an intranet. Data from the controller may also be anonymized. Anonymized data may be aggregated across patients for trends analysis. Data collected may include metadata such as patient ID, timestamp, patient medical history, such as weight, medications, etc. Use of the term “airway device” herein may include a controller component.
The airway device may have a portion within the mouth or be completely external. It may also be over the nose either instead of, or in addition to, the mouth. The airway device may purposefully block the nose. The airway device may also be incorporated into an endotracheal tube.
Gas outflow vent 216, in the exhalation airway lumen, may include a spirometry function. The vent may also maintain or cause to be maintained a slight positive pressure so that the airway of the subject remains open during breathing, which aids in the ability to sense certain parameters.
The air inflow, or inhalation airway lumen, and/or the exhalation airway lumen, may include one-way 218 valve to help direct exhaled air through the exhalation airway lumen during breathing.
Sensors 222, 224, and 226 may sense any of the parameters listed herewithin. Sensors may be placed in the exhalation airway lumen 210, the inhalation airway lumen 212, or on the outside of the airway device. Sensors 222 on the outside of the device will generally be for contact sensing with the mucosa and/or the lips, such as ECG sensors. Sensors 224 in the exhalation airway lumen may measure parameters associated with exhaled air, including pressure, flow, sounds, O2, CO2, urea, water vapor, alcohol, drugs, etc. Sensors 226 in the inhalation airway lumen may measure parameters associated with inhaled air, including O2, CO2, urea, water vapor, alcohol, drugs, etc.
Generally, the sensors can be placed anywhere along the length of the airway device, but there may be advantages to certain locations for certain types of sensors. For example, sensors for temperature, water vapor, alcohol, drugs etc. measured in exhaled air, would likely be better placed closer to the subject.
Flow and/or pressure sensors can be placed anywhere along the length of the airway device, but there may be an advantage to placing these sensors in a narrow and/or constant diameter section of the airway device such as within neck 208. A sensor or sensors may also be placed on gas outflow vent 216. Sensors may also be remote. For example, a pressure sensor, for example a pressure transducer, may be in fluid communication with the mouthpiece via a tube with an inner lumen.
A single use barrier may be used to cover mouthpiece section 206 to maintain sterility of the airway device. Alternatively, a disposable mouthpiece section may be attached to the airway device and removed after use. A heat-moisture exchanger may be used to prevent humidity from the breath entering into the device. Alternatively, the airway device may be sterilizeable or disposable.
Airway device 202 may incorporate hardware and/or software to either act as a controller, or communicate with a controller. The airway device may also act as a “partial controller”, where some of the controller activities take place within the airway device, and some take place within a separate controller device.
Airway device may be made out of any suitable material or materials, including polymer, metal, or any other material or any combination of materials. Airway device is preferably relatively light and portable.
Flow/pressure sensors may include orifice plates, pressure transducers, cone devices, Pitot tubes, Venturi tubes, flow nozzles, Fleisch or Lilly type pneumotachometers, or any other suitable technology. Sensor resolution is generally high. Pressure sensor sensitivity may around +/−0.5 mmHg. Pressure sensor sensitivity may around +/−1 mmHg. Pressure sensor sensitivity may around +/−2 mmHg. Alternatively, pressure sensor sensitivity may around +/−10 mmHg. Alternatively, pressure sensor sensitivity may around +/−20 mmHg.
The controller, whether it is separate from the airway device, or incorporated into the airway device, or some functions are located in the airway device and some located separately, may function as follows. The controller collects the data from the various sensors and analyzes them to determine cardiac output, stroke volume and/or cardiac function and/or other parameters. In addition, the controller may prompt the subject to help obtain the data from the sensors. For example, the controller may prompt the subject to hold his/her breath. The breath holding prompt may happen at certain phases of the breathing cycle, such as before or after inhalation and/or exhalation. The controller may prompt the subject to breath at a certain rate or to inhale, exhale, or hold his/her breath for a certain time period, or within a certain goal pressure range. Indicators may be present on the controller and/or the airway device to help the subject time certain activities, or achieve certain breathing goals, such as exhale pressure. For example, the controller may prompt the subject to hold his/her breath until a light on the controller and/or airway device turns green, or until an auditory signal is heard.
The controller may also determine whether the data it is collecting is adequate for analysis. For example, if the subject's airway is closing between breaths, or during exhalation, the data may be more difficult to analyze. The controller can sense when this is happening either by the pressure/flow profile or other parameters and can prompt the subject to adjust his/her breathing. For example, the controller may prompt the subject to breath more slowly, or to sit still. In addition, the controller may change the positive pressure of the airway device to help keep the airway open. Some possible prompts that the controller may provide to the subject are:
Other prompts are also possible. The prompts may change depending on the data being collected. For example, if the controller determines that the airway is closing between breaths, during breathing, or during exhalation, the prompts may tell the subject to breathe differently, or the controller may cause the airway device to apply positive pressure to the airway. In addition, the user may be prompted at certain time(s) of the day to use the device, so that the device is used at the same time each day. For example, the device may prompt the user to use the device upon waking.
Other parameters that may be considered in determining whether the subject's breathing is optimal for data collection include: variability of peak-to-peak period and magnitude, waveform shape, etc.
The controller may analyze the data from the sensors to determine other conditions, including COPD, asthma, CHF, cancer, stroke, pulmonary embolism, dyspnea, paroxysmal, nocturnal dyspnea, emphysema, and any other condition that could have an impact on respiratory rate, temperature, stroke volume, heart rate, tidal volume, lung sounds, heart sounds, GI sounds, pO2, pCO2, pH, alcohol, urea, drugs, or any other of the monitored parameters.
Vagal tone/vasovagal syndrome may also be determined using the present invention. Slight changes in heart beat parameters, including amplitude, rate, waveform shape, etc., at different stages of the breathing cycle can be measured and vagal tone determined. For example, if the heart rate increases during inhalation, this may indicate a high vagal tone.
As shown in
Typically, the input/output devices 1110 are coupled to the system through input/output controllers 1109. The volatile RAM 1105 is typically implemented as dynamic RAM (DRAM) which requires power continuously in order to refresh or maintain the data in the memory. The non-volatile memory 1106 is typically a magnetic hard drive, a magnetic optical drive, an optical drive, or a DVD RAM or other type of memory system which maintains data even after power is removed from the system. Typically, the non-volatile memory will also be a random access memory, although this is not required.
While
Some portions of the preceding detailed descriptions have been presented in terms of algorithms and symbolic representations of operations on data bits within a computer memory. These algorithmic descriptions and representations are the ways used by those skilled in the data processing arts to most effectively convey the substance of their work to others skilled in the art. An algorithm is here, and generally, conceived to be a self-consistent sequence of operations leading to a desired result. The operations are those requiring physical manipulations of physical quantities.
It should be borne in mind, however, that all of these and similar terms are to be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities. Unless specifically stated otherwise as apparent from the above discussion, it is appreciated that throughout the description, discussions utilizing terms such as those set forth in the claims below, refer to the action and processes of a computer system, or similar electronic computing device, that manipulates and transforms data represented as physical (electronic) quantities within the computer system's registers and memories into other data similarly represented as physical quantities within the computer system memories or registers or other such information storage, transmission or display devices.
The techniques shown in the figures can be implemented using code and data stored and executed on one or more electronic devices. Such electronic devices store and communicate (internally and/or with other electronic devices over a network) code and data using computer-readable media, such as non-transitory computer-readable storage media (e.g., magnetic disks; optical disks; random access memory; read only memory; flash memory devices; phase-change memory) and transitory computer-readable transmission media (e.g., electrical, optical, acoustical or other form of propagated signals—such as carrier waves, infrared signals, digital signals).
The processes or methods depicted in the figures herein may be performed by processing logic that comprises hardware (e.g. circuitry, dedicated logic, etc.), firmware, software (e.g., embodied on a non-transitory computer readable medium), or a combination of both. Although the processes or methods are described above in terms of some sequential operations, it should be appreciated that some of the operations described may be performed in a different order. Moreover, some operations may be performed in parallel rather than sequentially.
The mechanical high-pass filter isolates the higher frequency cardiac oscillation signal from the lower frequency pressure signal associated with natural breathing. This filter may employ a partially-impermeable barrier between differential sensing and reference inputs. The high-frequency cardiac oscillation signal is seen by the sensing input, whereas the pressure changes due to breathing are low frequency enough to equilibrate across the membrane and are detected at both inputs. By breathing into the device with a slight expiratory pause, or using the MVM, the cardiogenic oscillation signal can be reliably captured. Some embodiments may incorporate an additional, less sensitive, pressure sensor to monitor the entire breathing cycle and provide feedback to the patient about the size and frequency of the breaths, improving repeatability between measurements.
Note that the restrictor could be anything suitable, such as a flow control valve, a pressure control valve, etc.
Any of the embodiments herein can be adapted to be used inside the mouth, or partially inside the mouth. For example, an airway device deeper inside the mouth may be advantageous in keeping the airway open for cleaner pressure measurements. Furthermore, any of the embodiments herein may also be adapted to be used with patients who are tracheally intubated, in which case the devices described are attached to or in-line with the tracheal tube.
Embodiments of the airway device/controller may also be incorporated with a standard or specialized inhaler, for example for asthma. The airway device/controller in these embodiments may include a feature which tracks usage of the airway device and/or inhaler to monitor use compliance.
Embodiments of the airway device/controller may include integration with electronic health records (EMR) or electronic health records or other systems. For example, data from the controller may be transmitted wirelessly (or wired) to a server in the internet which integrates the data with that of an EMR. The patient ID (possibly anonymized) may be integrated into the metadata of the data transmitted by the controller so that the data can be integrated with the correct patient's medical record.
Data from multiple airway devices/controllers may be collected and aggregated and analyzed for trends. This data may be anonymized to comply with privacy rules.
In some embodiments of the airway device/controller, respiratory sinus arrhythmias (changes in heart rate due to breathing) may be tracked as an indicator of heart health or heart failure. Deviations from trends may be indicative of heart failure issues and may provide an alert. Because the data collected by the airway device may be continuous, for example, while the user sleeps, deviations from the norm (either for that patient or for a patient population) may indicate changes in health, and in particular, heart health.
In some embodiments of the airway device/controller, the device is used in an ambulatory manner. In other words, the user may use the device while walking around, watching TV, working, sleeping, resting, exercising or while performing everyday activities. The user is not tied to a stationary device, hospital nor clinic.
Sensors connected to the airway device/controller may include a blood oxygen saturation sensor or a blood CO2 saturation sensor or any other type of oxygen/CO2 sensor. For example, blood oxygen saturation may be determined by a pulse oximetry sensor in contact with the lips, tongue, oral mucosa and/or finger/extremities. This signal and/or an EKG signal collected from one or more EKG sensors (which may be in contact with these, or other, locations) may be used to determine pulse transit time.
Tissue O2/CO2 may be determined using an air tonometry sensor in contact with, or in proximity to, the tongue or oral mucosa or elsewhere. This type of sensor may include an air permeable membrane between the sensor and the body.
Absolute stroke volume may also be determined as follows. The volume or air displaced by each cardiac contraction due to pressure changes is determined by first determining the volume of air in the lungs. This may be done in one or more of several ways:
Stroke volume variability may also be determined/calculated. For example, the controller may prompt the user to breathe in deeply. The controller may use data captured from a sensor/sensors to determine stroke volume measurements at end inhalation and at end expiration—potentially to determine stroke volume variability. The controller may correct for changes in cardiac pulse size due to change in lung volume using spirometry (which measures breath volume) or the pulsed air method, or gas dilution techniques.
Spirometry may be used to measure one or more of several parameters, including: Vital capacity (VC), Forced vital capacity (FVC), Forced expiratory volume (FEV) at timed intervals of 0.5, 1.0 (FEV1), 2.0, 3.0 seconds, and other intervals, forced expiratory flow 25-75% (FEF 25-75), maximal voluntary ventilation (MVV), also known as Maximum breathing capacity, Peak Expiratory Flow (PEF), and any other parameters. Other tests may be performed. Results may be provided in raw data (liters, liters per second) and percent predicted—the test result as a percent of the “predicted values” for the patients of similar characteristics (height, age, sex, and sometimes race and weight), or the results may be provided in other ways.
In some embodiments of the airway device/controller, an ECG signal of the user is collected simultaneously to the cardiogenic oscillation data. In this way, the precise length and/or timing of a heartbeat can be determined (by the ECG signal) and the cardiogenic oscillation pressure curve can be divided up into precise heartbeats. In other words, one or more cardiogenic oscillation curves, each relating to one heartbeat, can be collected and identified and averaged, because the start and end of the cardiogenic oscillation curve relating to each heartbeat is precisely identified by the ECG signal. This allows collecting more than one cardiogenic oscillation curve and averaging them to get more accurate cardiogenic oscillation curve data. One or more ECG sensor/electrode(s) may be placed on the mouthpiece, or handheld portion of the airway device. ECG sensor/electrode(s) may be in contact with the user's mouth, finger(s), hand(s), or elsewhere on the body. Various features of the ECG curve may be used to “gate” the cardiogenic oscillation pressure curve. For example, the R peak, or alternatively the P, Q, S, T, U areas may be used.
Alternatively, or in addition, the signal from a pulse oximeter/photoplethysmograph may be used to gate the cardiogenic oscillation pressure curve in the same way—to determine the precise length/timing of the heartbeat. The same way a feature of the ECG curve can be used as a gating feature (for example, using the time between subsequent peaks of the R-wave), a feature, peak, valley, slope, length etc. of the pulse oximeter curve may be used instead of, or in addition to, the ECG curve. Multiple ECG and/or multiple pulse oximeter signals may alternatively be used. For example, the device may have electrodes/sensors for pulse oximeter and ECG for each hand, resulting in 2 ECG signals in addition to 2 pulse oximeter signals. This allows the best signal to be used to gate the cardiogenic oscillation pressure curve. The best signal may be chosen by amplitude, identifiable peak, consistency, etc. In this way, a good signal is likely to be obtained even if the user is not touching, or in contact with, all of the electrodes/sensors perfectly. Where redundant sensors are used to gate the cardiogenic oscillation pressure curve, the redundant sensors may be set with different gains on each. In this way, if one of the signals maxes out, or rails, where the peak of the curve is difficult to identify, another signal may be lower and have more identifiable peaks. This situation may occur if a user is pressing the sensors with a lot of pressure. In this way, one device with different sensors set with differing gains, may accommodate users with different finger pressures.
Outliers, or less useful data, may also be removed using ECG and/or pulse oximetry signals from the analysis to optimize the analysis results. More than one collected ECG/pulse oximetry signal may also be used in the analysis. One or more pulse oximeter/photoplethysmograph sensor/electrode(s) may be placed on the mouthpiece, or handheld portion of the airway device. Pulse oximeter/photoplethysmograph sensor/electrode(s) may be in contact with the user's mouth, finger(s), hand(s), or elsewhere on the body.
Alternatively, or in addition, the signal from the rough pressure sensor may be used to gate the cardiogenic pressure curve in the same way—to determine the precise length/timing of the heartbeat. Any sensor that determines and communicates the length/timing of a heartbeat to the controller may be used to gate the cardiogenic oscillation pressure curve.
In any of the gating curves, a regularly repeating feature, or peak, of the curve may be used to assess the quality or relative quality of the gating curve to be used as gating, as well as for the gating itself.
In the analysis shown in
Analysis of the shape of the cardiogenic oscillation curve may provide information on the patient. It is also patient specific, meaning that even among healthy patients, the cardiogenic oscillation curve shape is unique to each individual. In this way, the shape of the curve can be used as a signature to identify a patient. Changes in the cardiogenic oscillation curve may indicate specific disease states, or relative disease states. For example, the shape of the curve (or the change in the shape of the curve compared to normal or over time) may be analyzed to determine, and/or track over time, any of the following disease states.
In addition, changes to the shape of the cardiogenic oscillation curve over time, or with the patient in different positions, may indicate other patient parameters such as hydration. For example, a cardiogenic oscillation curve which appears to show improvement in PAC when the patient's legs are raised may be an indicator of dehydration. Hydration status may also be evaluated by changing the patient's position and/or breathing pressure. For example, the user may be prompted by the controller to take a measurement while standing, supine, sitting, legs raised, at a specific angle, inverted, etc. The relationship between or among these readings may be used in the data analysis to determine patient health. For example, the ratio between supine COS data and sitting COS data may be used in the analysis.
In some embodiments, any cardiovascular and/or pulmonary parameter may be collected in more than one patient position and the relationship between the parameters used to determine the health of the patient. For example, other available devices, such as the CardioMEMS™ device, manufactured by St. Jude Medical, may be used to collect a patient parameter, such as pulmonary artery pressure, when the patient is in more than one position. The data collected at these different positions can be used in conjunction with each another (for example, a ratio of data sitting and supine) to determine patient health.
In some embodiments of the airway device/controller, the user is prompted to breathe in one or more specific ways to obtain the pressure signal. The user may be asked to breathe (exhale, inhale or both or neither or MVM) into the device while simultaneously the controller controls a display which displays feedback on the pressure, the time, or other parameter, of the user's breathing. For example, the user may be asked to exhale at a steady pressure, within a pressure range, for a certain duration of time, and the display may show the user feedback on that pressure, and time, such as lights, a graphic display, or alternatively, the controller may provide audible feedback.
The graphical (or audible) display may also show the user when he/she is at the lower or higher end of the goal range (such as the pressure range), so that the user can make small adjustments to keep within range.
In some embodiments the goal exhale pressure is about 7 to about 8 mmHg. In some embodiments the goal exhale pressure is from about 9 to about 11 mmHg. In some embodiments the goal exhale pressure is from about 5 to about 7 mmHg. In some embodiments the goal exhale pressure is from about 5 to about 20 mmHg. In some embodiments the goal exhale pressure is from about 5 to about 15 mmHg. In some embodiments the goal exhale pressure is from about 10 to about 20 mmHg. In some embodiments the goal exhale pressure is from about to about 10 mmHg. In some embodiments the goal exhale pressure is from about 7.5 to about 12.5 mmHg.
In some embodiments the goal exhale time is about 5 seconds. In some embodiments the goal exhale time is about 4-6 seconds. In some embodiments the goal exhale time is about 3-7 seconds. In some embodiments the goal exhale time is about 2-5 seconds. In some embodiments, the goal exhale time is set anywhere up to 10 seconds.
Some components of the controller may also exist remotely, for example on an internet connected server, which is in communication with the local controller.
In some embodiments the airway device/controller is incorporated into a CPAP (Continuous Positive Airway Pressure) device. In these embodiments the controller may control the positive pressure delivered by the CPAP device based on the controller's analysis of the cardiogenic oscillation pressure curve.
In embodiments of the airway device which are combined with a CPAP device, or other positive pressure device, heart health may not only be diagnosed, but treated. Because the airway device measures the exact timing of heartbeats (via ECG, photoplethysmograph, rough breath pressure, cardiogenic oscillations, etc.), positive pressure can be applied through the airway to the lungs in synchrony with the heartbeat. Pulmonary pressure can be increased after ventricular contraction, and decreased before the next heart contraction, to offload the work of the heart.
Mechanical filters 2308 and 2310 help restrict and control the flow of air through the airway tubing. Inside the case, rough pressure sensor tubing 2312 is in fluid communication with rough pressure sensor 2318 and airway tubing 2304. Fine differential pressure sensor 2320 is in fluid communication with tubings 2314 and 2316 which are in fluid communication with rough pressure sensor tubing 2312. Inline flow restrictor 2322 is incorporated into tubing 2314 to restrict flow through one tubing in fluid communication with fine differential pressure sensor 2320. The other tubing, tubing 2316, either does not have a flow restrictor, or has a flow restrictor with a different restriction level than flow restrictor 2322. Flow restrictor 2322 may comprise one or more mechanical filters. The signal from rough pressure sensor 2318 may be subtracted from the signal from fine differential pressure sensor 2320 to remove artifacts from breathing, moving, coughing, etc. See
Fine pressure sensor sensitivity may be around +/−2 mmHg. Rough pressure sensor sensitivity may be around +/−10 mmHg. Alternatively, fine pressure sensor sensitivity may be around +/−0.5 mmHg—+/−3 mmHg. Rough pressure sensor sensitivity may be around +/−5 mmHg—+/−15 mmHg. Fine pressure sensor or rough pressure sensor may be differential pressure sensors.
As mentioned elsewhere herein, pulse transit time may be determined by evaluating the time between the ECG signal (for example, the R peak) and the heartbeat as measured by pulse oximetry/photoplethysmograph. Pulse transit time may also be determined by determining the time between ECG signal and a peak in the cardiogenic oscillation curve. This may provide different information including heart valve opening pressure and/or opening times.
This embodiment includes resistance control orifice 2606 which controls the resistance felt by the user while blowing through the mouthpiece. In some embodiments, the user is asked to exhale at a relative constant exhale pressure for about 1 to 5 or about 5 to 10 seconds. The resistance control orifice can control the exhale resistance. A smaller sized resistance control orifice will equate to a higher exhale resistance. A larger sized resistance control orifice, or multiple resistance orifices, will result in a lower exhale resistance. Preferably, the resistance control orifice is approximately circular in shape and ranges from about 0.3 mm to about 0.5 mm in diameter or longest dimension. Alternatively, the longest dimension of the resistance control orifice is from about 0.1 mm to about 1.0 mm. Alternatively, the longest dimension of the resistance control orifice is from about 0.5 mm to about 1.0 mm.
Filter segment 2608 may adapt to mouthpiece 2602 and/or airway tubing 2610 by a common luer type adapter or any other suitable adapter such as luer-lock, screw on, snap on, glue on adapter etc.
When holding the sensor hand piece, a user will preferably have one or both thumbs in contact with pulse sensor(s) 2704, and one or more fingers in contact with ECG electrode(s) 2802. Preferably, before the user places his/her fingers/thumbs on the sensors, he/she will place the mouthpiece in his/her mouth. However, if only one hand is necessary for the sensor contacts, the mouthpiece may be placed in the user's mouth at any time before testing begins.
During data collection, the user is guided through various steps either by display 2714, or audibly or both. Alternatively the display may be on the user's mobile phone/computer with other functions of the sensor hand piece in communication with the mobile phone/computer either by a wired connection, a wireless connection, or direct connection via a port in the mobile phone/computer. Indicator(s) 2710 may be lights, a visual bar, audible sounds, tactile feedback (such as vibration) etc. in this figure, the indicators are lights which indicate the exhale pressure as well as the consistency of the exhale pressure, and may also indicate when the exhale pressure has been consistently in the proper pressure range for the required time. Preferably, the user is guided by the indicators to hold a steady pressure. In addition or alternatively, the user is guided by the indicators to hold a particular target pressure. A target pressure may be preset or may be set depending on the individual user and the user's comfortable exhale pressure range for holding a steady exhale pressure. Pressure goal indicator 2712 may be fixed in place or may be movable to suit individual users. The software may also include the ability to adjust indicators 2710 so that goal indicator 2712 stays in the same location, but refers to different exhale pressures for different individuals. For example, as part of a set up procedure, the user may be asked to exhale at a comfortable pressure for x seconds. A button on the device may be pressed to set that pressure as the “goal” pressure for the particular individual.
Data 2906 transferred from the sensor hand piece includes Device ID (the unique identifier of the hand piece, which may be in the form of a MAC address or other ID), Data File ID (the unique identifier of the data file within the device), Treatment data, Position data (sitting, lying down, etc.), Pass/Fail data (related to whether sensor data collected is adequate for analysis, may also be adequacy level data), Timestamp(s), ECG data, pulse oximeter/photoplethysmograph data, Breath data, and other relevant data.
Sensor hand piece 2902 may incorporate any of the embodiments disclosed herein. Server 2908 may be remote or local, and may be on the internet, intranet or local network. Dashboard computer 2910 may have different access rights. For example, the patient/airway device user may have one access level, where a physician or an insurance company or a clinical trial administer or another type of administrator may have another access level. Data may be displayed in various ways depending on the user. For example, a clinical trial administrator may see data aggregated from more than one user, but may not see the identity of the users. The patient may see only his/her data and may see trends, alerts, suggestions etc. The patient's physician may see the data of several patients, each identified, with alerts, data trends, etc. The dashboard computer, or server, may be integrated with an electronic health record. Data from the airway device may be integrated with a patient's personal electronic health record. Data from the airway device may be used to make diagnoses either with or without data from other devices/sources. Server 2908 may include algorithms which incorporate and analyze data from the airway device and optionally other data collection devices to predict outcomes.
Screen 3016 shows a screen that indicates that adequate ECG and pulse signals are being obtained. The user is then instructed to begin breathing. Breathing may mean natural breathing or a prolonged steady exhale or inhale. Preferably, the user is asked to produce a steady prolonged exhale. Again, the system evaluates the signal to determine if the breath signal is adequate or inadequate. The adequacy of a breath signal may include length of signal, consistency of signal, magnitude of signal, shape of signal (such as the pressure signal), existence of regular peaks, etc. Screen 3018 shows a sample screen which may be displayed if the breath signal is determined to be inadequate. The screen may provide additional information such as length of breath, steadiness of breath, magnitude of breath etc. For example, here the user is asked to breath for at least 10 seconds. The user is also asked to breath in the middle of the “white zone”, meaning to breathe so that indicators 2710 shown in
Screen 3020 shows the progress of the test when breath, ECG and pulse signals are all adequate. The system may analyze the results in real time to determine whether the total signal is adequate, meaning it can be analyzed properly. If the signal cannot be analyzed property, the user may be prompted to repeat the test.
Screen 3022 shows the beginning of the next test, which differs from the previous test by position. This screen, for example, shows that the user should now lie down. Once the user is lying down and presses the mode button, screens similar to those shown in screens 3008 through 3020 will be shown. Other factors in addition to position may be changed for different tests. For example, the user may be asked to exercise between tests, or breathe differently or for a different length of time. Screen 3024 is a sample end screen when all testing for the session is complete.
Some embodiments of the airway device include capabilities to communicate with caregivers, such as physicians, nurses, family, neighbors, etc. This communication may happen wirelessly via a wi-fi connection or via a cell connection. Alternatively, the communication may happen in a wired configuration. This communication may be with a network or directly peer-to-peer. The network may be the internet, intranet or other network. These communications may help caregivers monitor a user's health status. For example, data may be communicated which relates to congestive heart failure, PAC, pulmonary issues (such as COPD, emphysema, asthma, lung capacity, lung sounds, asthma, shortness of breath, etc.), other cardiac issues (such as atrial fibrillation, valve regurgitation or prolapse, plaque buildup, heart murmurs, heart sounds, etc.), diabetes, stroke, nutrition, medication adherence, routine adherence, physical strength, physical dexterity, hydration, temperature, blood pressure, heart rate, respiratory rate, tidal volume, ECG, breathing sounds, saliva chemistry, breath chemistry, steadiness/tremors, hearing, etc. These conditions may be monitored over time and changes in patterns may indicate a problem and may be communicated to one or more caregivers. Alternatively, certain thresholds may be predefined or “learned” from the data which trigger an alert to a caregiver. Effectiveness of various treatments may also be monitored over time.
In situations where data is transmitted via a network, privacy is of utmost concern. The data may be encrypted, anonymized etc. to adhere to HIPAA standards. In addition, the identity of the user may be confirmed based on data consistency (data for a session is similar enough to the data of past sessions), fingerprint ID (may be gathered from the pads on the handheld portion of the device or elsewhere, such as on a mobile phone screen), DNA ID (may be gathered from saliva or elsewhere), survey questions etc.
More specifically, pulmonary diseases, such as COPD, emphysema, asthma etc, may be monitored by a spirometer, or other way of measuring breath flow. For example, breath flow may be measured by ultrasonic, Doppler, mechanically (as in a pinwheel type device) etc. A microphone may be incorporated into the airway device to detect lung sounds such as crackling or wheezing, which may be an indicator of fluid in the lungs or other problems with the lungs. Adherence and/or effectiveness of medications may be monitored by looking at this type of data over time, to see if symptoms/conditions worsen or get better. Also, chemical markers in the breath and saliva can be monitored to confirm use of certain medications/treatments.
In addition to monitoring heart failure conditions (described extensively herein), other cardiovascular conditions such as AFIB (atrial fibrillation), valve issues (regurgitation, irregularities, etc.), plaque buildup may also be monitored. For example, a microphone may be incorporated into the airway device to detect heart sounds such as those associated with valve regurgitation, irregularities, and/or atrial fibrillation. One or more ECG sensors may be incorporated into the handheld portion of the airway device or elsewhere on the device to monitor the ECG. In addition, PAC (described elsewhere herein) is also useful in monitoring heart conditions other than heart failure. For example, PAC may be used to monitor the buildup of plaque, or other issues within the cardiovascular arteries.
The airway device shown in
The device is used with cap 3218 in place to assess cardiovascular health. In this mode, the user is prompted by the controller to contact sensors 3212 in a particular way (sensor contact may also be requested by the controller in pulmonary function mode). The user is also prompted by the controller to exhale into the mouthpiece with the throat open, for example via a MVM. Indicators on display 3214, or audible or tactile indicators may help the user perform the MVM at the required pressure for the required period of time, and in the required position(s). Buttons 3216 may serve other functions, such as on/off, display settings, navigation etc. Data may be transmitted from the device wirelessly via Bluetooth, wifi, cellular network etc. Data may also be transferred via a wired connection, such as USB. Pressure transducer 3211 may be incorporated into cap 3218 or may be incorporated into the sensor hand-piece body. Display 3214 may be on the sensor hand-piece body, or may be on a mobile device, such as a mobile phone or tablet, or the display may be incorporated into both devices.
As mentioned elsewhere herein, cardiogenic oscillations are detectable during a “modified Valsalva maneuver” or MVM, where the user has his/her throat open (i.e., leaving the glottis and/or epiglottis open) during exhalation against pressure. This is referred to as a “modified Valsalva maneuver” or MVM. The patient/user may be prompted to exhale within a specific pressure range and for a specific time period. The user may be prompted by the controller, or instructed, to perform the MVM within the proper parameters (open throat, pressure, and time).
To ensure that the user is performing the MVM properly, the user may be instructed to perform use a training app. The training app may be part of the controller function (i.e., an app on a mobile phone, which is in communication with a sensing hand-piece). The training app may prompt the user to place the mouthpiece in his mouth, and place his fingers/thumbs on the sensors on the sensor hand-piece. The training app may then ask the user to exhale into the mouthpiece while holding the sensor hand-piece. The user will be asked to exhale with his throat open, at a steady pressure indicated on the display, for a set time period. For example, the user may be asked to exhale at a steady pressure, for 5 seconds, so that a light indicator on the display remains within an indicated range. The app may then display the results of the test. Examples of displayed data are shown in
In some embodiments, the signal curve data for the various sensors is analyzed for shape in a similar manner by the controller. In these embodiments, the data may not be displayed on the display. The controller (or user) may only need one acceptable gating signal (ECG or either photoplethysmograph signal) and an acceptable COS signal to prompt the user to continue to the actual data collection. For example, if the left photoplethysmograph signal and the COS signal are acceptable, the left photoplethysmograph signal may be used to gate the COS signal.
If the ECG signal is unacceptable, the user may be prompted by the controller to contact the ECG sensor differently, for example with more pressure, less pressure, or with more sensor coverage. If the photoplethysmograph signal is unacceptable, the user may be prompted by the controller to contact the ECG sensor differently, for example with more, less pressure or with more sensor coverage. If the COS signal is unacceptable, the user may be prompted by the controller to breathe differently, for example, to hold breath more steady (if rough pressure sensor has determined that the exhale pressure was not within range for long enough, or if COS signal curve does not have identifiable peaks), to exhale for longer (if rough pressure sensor has determined that the exhale pressure was not within range for long enough or if not enough identifiable peaks are available), to exhale with more or less pressure, to open his throat while exhaling (if COS curve does not have identifiable peaks) etc.
Once the user has obtained acceptable data via the training app, he may move on to actual data collection for analysis and trending. The user may periodically be prompted by the controller to fill out a survey concerning his/her health. The survey may be requested once/data collection session, or at any other interval, for example once/day, once/week, once/month, etc.
Some embodiments of the airway device may include one or more accelerometers on the handheld portion of the device. Data from accelerometers may be used to sense the position of the device to ensure proper positioning (for example, is the subject lying down or sitting based on the angle), or the existence or worsening of tremors.
Some embodiments of the airway device may include a speaker to introduce sounds into the mouthpiece/tube. Some embodiments may include a hearing test—for example, touching certain sensors on the handheld portion in response to auditory tones created by the controller.
Some embodiments of the airway device may include impedance sensors (for example on the mouthpiece, or on the handheld portion, contacting one or both hands). For example, 2 separate impedance sensors may be on the handheld portion—one for the left hand and one for the right hand, so that impedance measurements can be taken across hands. Impedance measurements can determine user hydration. Data from the impedance sensors may be used alone or in conjunction with data from other sensors. For example, impedance data may be used in conjunction with PAC data to determine user hydration. Impedance measurements may also be used to determine user body weight and/or fat composition.
Some embodiments of the airway device may be able to monitor diabetes, for example by monitoring analytes in saliva, breath or on the skin.
Some embodiments of the airway device collect data on usage patterns in addition to physiological data to determine whether the user is straying from routine. Straying from routine may be an indicator of a health issue such as stroke, dementia, etc.
Some embodiments of the airway device include one or more strain gauges on the handheld portion to determine finger pressure. These data may be used for device usage compliance (is the user positioning his/her fingers appropriately on the device) and/or for physiological data such as finger strength or steadiness. Some embodiments may include a dexterity test, where the user is asked to touch certain sensors quickly, or in a test pattern, which is indicated by sounds and/or lights or other indicators produced by the controller.
Some embodiments of the airway device are calibrated using data across multiple users of multiple disease states. Alternatively or additionally, some embodiments of the airway device may be calibrated using data learned from the subject user over time, optionally augmented with surveys or other means of obtaining health related information.
This application is a continuation of U.S. application Ser. No. 15/863,722 filed Jan. 5, 2018, which is a continuation of PCT/US2016/061993 filed Nov. 15, 2016, which claims the benefit of priority to U.S. Provisional Application No. 62/255,915 filed Nov. 16, 2015 and U.S. Provisional Application No. 62/264,734 filed Dec. 8, 2015 and U.S. Provisional Application No. 62/302,684 filed Mar. 2, 2016 and U.S. Provisional Application No. 62/331,263 filed May 3, 2016 and U.S. Provisional Application No. 62/402,244 filed Sep. 30, 2016, each of which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 62255915 | Nov 2015 | US | |
| 62264734 | Dec 2015 | US | |
| 62302684 | Mar 2016 | US | |
| 62402244 | Sep 2016 | US | |
| 62331263 | May 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15863722 | Jan 2018 | US |
| Child | 18328414 | US | |
| Parent | PCT/US2016/061993 | Nov 2016 | US |
| Child | 15863722 | US |
